Drug Profile
PN 2034
Alternative Names: PN-2034; SAR 176975Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Wellstat Therapeutics Corporation
- Developer Sanofi; Wellstat Therapeutics Corporation
- Class Antihyperglycaemics; Small molecules
- Mechanism of Action Peroxisome proliferator-activated receptor gamma agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Type 2 diabetes mellitus